🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "huge turning point" in the fight against increasingly resistant strains of the pathogen, according to scientists.

A Worldwide Health Concern

Gonorrhoea infections are escalating around the world, with figures suggesting more than 82 million infections each year. Notably increased rates are reported in Africa and nations within the WHO's designated area, which spans from China and Mongolia to New Zealand. Within England, cases have reached a historical peak, while figures across Europe in 2023 were triple the level compared to those in 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune advancement in the context of increasing worldwide cases, increasing antimicrobial resistance and the highly restricted therapeutic options presently on offer.”

Health officials are deeply concerned about the surge in treatment-resistant strains. The World Health Organization has listed it as a "critical concern". Ongoing monitoring found that resistance to standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Therapies Gain Clearance

Zoliflodacin, marketed under the name a brand name, was approved by the US FDA in recent days for use against gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Researchers believe that focused deployment of this new drug will help delay the spread of drug resistance.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, also received approval in concurrent days. This medication, which is additionally indicated for UTIs, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment stemmed from a new, not-for-profit approach for antibiotic development. The charitable organization GARDP collaborated with the pharmaceutical company Innoviva to develop it.

“This approval represents a huge turning point in the therapy of multidrug-resistant gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Research Study Data and Global Access

As per data published in a prominent scientific publication, zoliflodacin successfully treated over nine in ten of genital gonorrhoea infections. This places it at an comparable level with the typical regimen, which uses two antibiotics. The trial included nearly 1,000 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, GARDP has the authority to license and sell the drug in a wide range of developing nations.

Doctors on the front lines have voiced positive views. The availability of a one-pill regimen such as this is seen as a "revolutionary step" for managing the epidemic. This is considered vital to lessen the impact of the disease for individuals and to halt the transmission of untreatable gonorrhoea around the world.